Table 1.
Demographics and clinical characteristics.
| Total (n=2347) | Non-survivor (n=57) | Survivor (n=2290) | P-value | |
|---|---|---|---|---|
| Age (years) | 72.19 ± 16.41 | 83.70 ± 9.49 | 71.90 ± 16.45 | < `0.001 |
| Gender | 0.196 | |||
| Female | 1369 (58.3) | 38 (66.7) | 1331 (58.1) | |
| Male | 978 (41.7) | 19 (33.3) | 959 (41.9) | |
| LOS (days) | 10 (6-14) | 7 (4-11) | 10 (6-14) | < 0.001 |
| Laboratory findings | ||||
| White blood cell count (109/L) | 5.25 (4.14-6.84) | 7.24 (5.56-9.53) | 5.22 (4.11-6.77) | < 0.001 |
| Lymphocyte count (109/L) | 1.35 (0.94-1.84) | 0.95 (0.58-1.33) | 1.36 (0.95-1.84) | 0.003 |
| Monocyte count (109/L) | 0.43 (0.33-0.56) | 0.37 (0.28-0.63) | 0.43 (0.33-0.56) | 0.89 |
| Neutrophil count (109/L) | 3.21 (2.28-4.52) | 5.92 (3.92-7.63) | 3.17 (2.27-4.45) | < 0.001 |
| Eosinophil count (109/L) | 0.05 (0.02-0.11) | 0.01 (0-0.05) | 0.05 (0.02-0.11) | 0.003 |
| Basophil count (109/L) | 0.01 (0.01-0.02) | 0.01 (0-0.01) | 0.01 (0-0.02) | < 0.001 |
| Platelet count (109/L) | 183 (145-229) | 179 (127-231) | 183 (145-229) | 0.56 |
| dNLR | 1.65 (1.14-2.46) | 4.05 (2.30-6.53) | 1.64 (1.13-2.39) | < 0.001 |
| NLR | 2.35 (1.52-3.82) | 6.01 (3.31-11.76) | 2.31 (1.51-3.72) | < 0.001 |
| SII | 429 (262-751) | 1079 (612-2016) | 423 (260-723) | < 0.001 |
| SIRI | 1.02 (0.57-1.87) | 2.26 (1.20-5.23) | 1.00 (0.57-1.81) | < 0.001 |
| PLR | 134 (100-192) | 204 (120-310) | 133 (99-189) | < 0.001 |
| MLR | 0.32 (0.22-0.48) | 0.42 (0.27-0.83) | 0.31 (0.22-0.48) | 0.002 |
| Treatments | ||||
| ICU | 84 (3.6) | 13 (22.8) | 71 (3.1) | < 0.001 |
| CRRT | 16 (0.7) | 1 (1.8) | 15 (0.7) | 0.326 |
| Primary care | 539 (23.0) | 39 (68.4) | 500 (21.8) | < 0.001 |
| High fever | 189 (8.1) | 17 (29.8) | 172 (7.5) | < 0.001 |
| Antibiotics | 498 (21.2) | 46 (80.7) | 452 (19.7) | < 0.001 |
| High flow ventilation | 60 (2.6) | 4 (7.0) | 56 (2.4) | 0.083 |
| Noninvasive ventilation | 108 (4.6) | 17 (29.8) | 91 (4.0) | < 0.001 |
| Invasive ventilation | 29 (1.2) | 10 (17.5) | 19 (0.8) | < 0.001 |
| Comorbidities | 1439 (61.3) | 37 (64.9) | 1402 (61.2) | 0.572 |
| Hypertension | 1010 (43) | 24 (42.1) | 986 (43.1) | 0.886 |
| Diabetes | 449 (19.1) | 14 (24.6) | 435 (19.0) | 0.291 |
| Heart disease | 514 (21.9) | 10 (17.5) | 504 (22.0) | 0.421 |
| Malignant tumor | 152 (6.5) | 6 (10.5) | 146 (6.4) | 0.208 |
| Lung disease | 173 (7.4) | 4 (7.0) | 169 (7.4) | 0.208 |
| Kidney disease | 97 (4.1) | 2 (3.5) | 95 (4.1) | 1 |
| Brain disease | 383 (16.3) | 10 (17.5) | 373 (16.3) | 0.8 |
| Disease severity | < 0.001 | |||
| Asymptomatic | 356 (15.2) | 1 (1.8) | 355 (15.5) | |
| Mild | 788 (33.6) | 4 (7.0) | 784 (34.2) | |
| Common | 867 (36.9) | 2 (3.5) | 865 (37.8) | |
| Severe | 191 (8.1) | 25 (43.9) | 166 (7.2) | |
| Critically severe | 145 (6.2) | 25 (43.9) | 120 (5.2) | |
Values are presented as mean ± standard, frequency (%), or median (inter-quartile range). LOS, length of hospitalization; dNLR, derived neutrophil to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; PLR, platelet to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; ICU, intensive care unit; CRRT, continuous renal replacement therapy.